1. Home
  2. LPA vs ATYR Comparison

LPA vs ATYR Comparison

Compare LPA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$3.27

Market Cap

79.0M

Sector

N/A

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.80

Market Cap

73.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
ATYR
Founded
2013
2005
Country
United States
United States
Employees
N/A
58
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
73.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LPA
ATYR
Price
$3.27
$0.80
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$3.67
AVG Volume (30 Days)
19.6K
939.9K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$0.64
52 Week High
$9.41
$7.29

Technical Indicators

Market Signals
Indicator
LPA
ATYR
Relative Strength Index (RSI) 65.13 44.45
Support Level $2.51 $0.68
Resistance Level $3.66 $0.85
Average True Range (ATR) 0.24 0.05
MACD 0.01 0.00
Stochastic Oscillator 65.04 48.87

Price Performance

Historical Comparison
LPA
ATYR

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Share on Social Networks: